(EAY 131 Master Protocol) Molecular Analysis for Therapy Choice (MATCH)
This trial aims to establish whether patients with tumor mutations, amplifications or translocations in one of the genetic pathways of interest are likely to derive clinical benefit (primary objective: objective response; secondary objective: progression-free survival of at least 6 months) if treated with agents targeting that specific pathway in a single-arm design.
Study Number: 

NCG 275215

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.